3D Medicines Inc.
HKSE: 1244.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zhaolong Gong
- Employees
- 191
- Headquarters
- Qingdao, China
- IPO year
- 2022
- Market cap
- HK$734.9M
- Website
- https://www.3d-medicines.com
Loading 1244…
Loading profile data…Frequently asked questions about 1244
What does 3D Medicines Inc. (1244.HK) do?
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high...
Where does 1244.HK trade?
3D Medicines Inc. (1244.HK) trades on the Hong Kong Stock Exchange.
What sector is 1244.HK in?
3D Medicines Inc. (1244.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of 3D Medicines Inc.?
Zhaolong Gong is the chief executive officer of 3D Medicines Inc. (1244.HK).
Where is 3D Medicines Inc. headquartered?
3D Medicines Inc. is headquartered in China.
Does 1244.HK pay a dividend?
3D Medicines Inc. (1244.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 1244.HK go public?
3D Medicines Inc. (1244.HK) completed its initial public offering in 2022.